Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...